Pancreatic cancer: trials for referral
1216 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
400 trials shown · Showing the 400 most recently updated of 1216 open trials.
Phase 21 site
RecruitingUnited States
NCT03492671
Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
Loma Linda University
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 10 sites
Not yet recruiting
NCT07859085
A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma
Genentech, Inc.
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govNo phase5 sites
Not yet recruitingChina
NCT07928362
A Multicenter, Prospective Single-arm Study of Multimodal Thermal Therapy Combined With Toripalimab and AG Chemotherapy in the Treatment of Advanced Pancreatic Cancer
Ruijin Hospital
Pre-treatment window Registry sentence: “No prior systemic therapy for pancreatic cancer;”
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingSingapore
NCT07929961
Study of MC001 in Patients With Advanced Solid Tumours
National University Hospital, Singapore
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 285 sites
RecruitingAustralia, Canada, Chile, China, Germany, Denmark
NCT04924075
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Merck Sharp & Dohme LLC
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 1/222 sites
RecruitingAustralia, Spain, France, United States
NCT07020221
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingChina
NCT07802184
GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Metastatic PDAC
West China Hospital
Pre-treatment window Registry sentence: “\) Age 18-75 years, regardless of sex; 2) patients with histologically confirmed pancreatic ductal adenocarcinoma (PDAC); 3) previously untreated patients with metastatic PDAC, with at least one measurable lesion according to RECIST v1.1, and target lesions must not have received prior radiotherapy or local treatment; 4) ECOG performance status of 0-1; 5) life expectancy ≥3 months; 6) willingness to comply with study procedures and able to receive treatment and undergo follow-up; 7) adequate major organ function, with laboratory test results meeting the following criteria within 7 days before enrollment: white blood cell (WBC) count ≥2.5×10⁹/L, absolute neutrophil count (ANC) ≥1.5×10⁹/L, platelet (PLT) count ≥75×10⁹/L, hemoglobin (HGB) ≥90 g/L (without blood transfusion or erythropoietin \[EPO\] dependence within 7 days), total bilirubin (TBIL) ≤1.5× the upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5×ULN, albumin ≥30 g/L, international normalized ratio (INR) ≤1.5×ULN, serum creatinine (Cr) ≤1.5×ULN, and urinary protein ≤1+; 8) patients who are hepatitis B surface antigen (HBsAg)-positive with a peripheral blood hepatitis B virus DNA (HBV-DNA) level ≤1×10³/L; patients who are HBsAg-positive with a peripheral blood HBV-DNA level ≥1×10³/L may also be eligible if, in the investigator's judgment, chronic hepatitis B is clinically stable and does not increase the patient's risk; 9) voluntary participation in the study and provision of written informed consent.”
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT01174121
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Cancer Institute (NCI)
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 12 sites
RecruitingUnited States
NCT04222413
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
National Cancer Institute (NCI)
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govNo phase5 sites
RecruitingSouth Korea, United States
NCT07325214
Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer
IMGT Co., Ltd.
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 3118 sites
RecruitingUnited States
NCT06807437
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
SWOG Cancer Research Network
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 113 sites
RecruitingCanada, South Korea, United States
NCT06983743
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Erasca, Inc.
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT07828236
Lm-LLO-TT and Gemcitabine in Unresectable Pancreatic Ductal Adenocarcinoma
Loki Therapeutics, Inc.
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 325 sites
RecruitingAustria, United Kingdom, Italy, Netherlands, United States
NCT07621718
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Revolution Medicines, Inc.
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT07829185
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
University of Oklahoma
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 238 sites
RecruitingAustralia, Canada, Puerto Rico, United States
NCT07644559
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Verastem, Inc.
Pre-treatment window Registry sentence: “Treatment-naïve or received ≤ 1 cycle of SoC for metastatic disease”
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 36 sites
RecruitingUnited States
NCT07805954
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
Revolution Medicines, Inc.
Pre-treatment window Registry sentence: “No prior treatment in the locally advanced unresectable or metastatic setting”
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govNo phase46 sites
RecruitingUnited States
NCT06995898
The Vanguard Study: Testing a New Way to Screen for Cancer
National Cancer Institute (NCI)
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
By invitation onlyChina
NCT07920731
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Fudan University
Pre-treatment window Registry sentence: “No prior systemic therapy for pancreatic cancer (including chemotherapy, targeted therapy, or immunotherapy).”
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 3132 sites
RecruitingAustralia, Belgium, Czechia, Germany, Spain, France
NCT07562152
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Immuneering Corporation
Pre-treatment window Registry sentence: “Participants must be treatment naive as follows:”
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 12 sites
RecruitingUnited States
NCT06141031
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govNo phase6 sites
RecruitingUnited States
NCT07817147
CREO - Microwave Ablation Feasibility Study
Banner Health
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 130 sites
RecruitingCanada, China, Spain, United Kingdom, Puerto Rico, United States
NCT07090499
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Pfizer
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 1/223 sites
RecruitingSwitzerland, Denmark, Spain, Finland, France, United Kingdom
NCT07563738
A 2-part Phase 1/2 Open-label Trial on ODM-212
Orion Corporation, Orion Pharma
Pre-treatment window Registry sentence: “Sotorasib cohort, treatment naïve: Participants with histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC and a KRAS G12C-mutation, confirmed using a validated test, who are eligible for a treatment with sotorasib and have not received a KRAS G12C inhibitor as prior treatment.”
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT06885697
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Cancer Institute (NCI)
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 23 sites
RecruitingUnited States
NCT05132504
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
Baylor College of Medicine
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 2456 sites
RecruitingIsrael, Puerto Rico, United States
NCT04858334
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
National Cancer Institute (NCI)
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 242 sites
RecruitingSpain, Georgia, South Korea, United States
NCT06695845
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 1/213 sites
RecruitingPuerto Rico, United States
NCT03556228
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingChina
NCT07777211
A Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer
Beijing Gene Key Life Technology Co., Ltd
Pre-treatment window Registry sentence: “No prior systemic therapy for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma.”
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States228 open trials
- China104 open trials
- Spain51 open trials
- France41 open trials
- Australia41 open trials
- Canada38 open trials
- South Korea35 open trials
- United Kingdom34 open trials
- Japan33 open trials
- Italy33 open trials
- Germany23 open trials
- Netherlands18 open trials
- Belgium17 open trials
- Taiwan13 open trials
- Poland11 open trials
- Sweden10 open trials
- Israel10 open trials
- Denmark8 open trials
- Singapore7 open trials
- Puerto Rico7 open trials
- Norway6 open trials
- Switzerland6 open trials
- Brazil6 open trials
- Austria5 open trials
- Hungary4 open trials
- Georgia4 open trials
- Türkiye3 open trials
- Chile3 open trials
- Finland3 open trials
- Hong Kong3 open trials
- Ireland3 open trials
- Mexico3 open trials
- Egypt3 open trials
- Portugal2 open trials
- Czechia2 open trials
- Russia1 open trial
- Romania1 open trial
- Argentina1 open trial
- Panama1 open trial
- Slovakia1 open trial
- India1 open trial
- Bulgaria1 open trial
- Malaysia1 open trial
- Moldova1 open trial
- New Caledonia1 open trial
- Réunion1 open trial
- Guadeloupe1 open trial
- Martinique1 open trial
- Ukraine1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Cancer Hospital of Chinese Academy of Medical Sciences
Beijing, China
6 trials · 26 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
Status changed: Running, not recruiting → Completed
WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment
NCT06291324 · No phase · United States
Source: ClinicalTrials.govClosed for recruitment
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
NCT02584244 · Phase 1/2 · United States
Source: ClinicalTrials.govClosed for recruitment
Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
NCT06454383 · Phase 1 · United States
Source: ClinicalTrials.govNew in the registry
Study of MC001 in Patients With Advanced Solid Tumours
NCT07929961 · Phase 1 · Singapore
Source: ClinicalTrials.govOpened for recruitment
SIL204-SL Treatment for Locally Advanced Pancreatic Cancer
2025-525157-39-00 · Phase 2/3 · Germany
Source: EU CTISOpened for recruitment
GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Metastatic PDAC
NCT07802184 · Phase 1/2 · China
Source: ClinicalTrials.govNew in the registry
Endoscopic Ultrasound Shear Wave Elastography in Solid Pancreatic Lesions
NCT07924540 · No phase · Romania
Source: ClinicalTrials.govPhase changed: No phase → Phase 1/2
Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN
NCT06735560 · Phase 1/2 · France
Source: ClinicalTrials.govOpened for recruitment
Lm-LLO-TT and Gemcitabine in Unresectable Pancreatic Ductal Adenocarcinoma
NCT07828236 · Phase 1 · United States
Source: ClinicalTrials.govOpened for recruitment
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
NCT07829185 · Phase 1 · United States
Source: ClinicalTrials.govStopped early
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
NCT05723107 · Phase 1 · United States
Source: ClinicalTrials.govOpened for recruitment
Feasibility and Effectiveness of Three-day Discharge After Distal Pancreatectomy
NCT07095621 · No phase · Italy
Source: ClinicalTrials.govNew in the registry
AI-Assisted Differentiation of Pancreatic Cystic Lesions Using EUS Images and Clinical Features
NCT07919704 · No phase · China
Source: ClinicalTrials.gov
Show more
Stopped early
CT-95 in Advanced Cancers Associated With Mesothelin Expression
NCT06756035 · Phase 1 · United States
Source: ClinicalTrials.govOpened for recruitment
BEFAST Study, [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer
NCT07629609 · Phase 2 · Denmark
Source: ClinicalTrials.govClosed for recruitment
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185 · Phase 1 · Belgium, Germany, Spain, France, Italy, Japan
Source: ClinicalTrials.govOpened for recruitment
PET-imaging of Two Vartumabs in Patients With Solid Tumors
NCT06645808 · Early Phase 1 · Netherlands
Source: ClinicalTrials.govPhase changed: Phase 1 → Early Phase 1
PET-imaging of Two Vartumabs in Patients With Solid Tumors
NCT06645808 · Early Phase 1 · Netherlands
Source: ClinicalTrials.govPhase changed: Phase 3 → Phase 2
NCT06390059 · Phase 2 · Switzerland, Czechia, Germany, Spain
Source: ClinicalTrials.govPhase changed: Phase 1/2 → Phase 2
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941 · Phase 2 · Australia, Canada, China, Spain, United Kingdom, Georgia
Source: ClinicalTrials.govPhase changed: Phase 1 → Phase 1/2
A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer
NCT05586516 · Phase 1/2 · United Kingdom, Italy
Source: ClinicalTrials.govOpened for recruitment
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171 · Phase 2/3 · Austria, Australia, Belgium, Germany, Spain, France
Source: ClinicalTrials.govClosed for recruitment
NCT05141149 · Phase 1/2 · Australia, Spain, Singapore, United States
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05143970 · Phase 1 · Belgium, France
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT04827953 · Phase 1/2 · Spain
Source: ClinicalTrials.govPhase changed: Phase 2 → Phase 1/2
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer
NCT04821284 · Phase 1/2 · Norway, United States
Source: ClinicalTrials.govClosed for recruitment
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
NCT04927780 · Phase 3 · Netherlands, Sweden
Source: ClinicalTrials.govClosed for recruitment
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
NCT04421963 · Phase 3 · Belgium, Bulgaria, Canada, China, Czechia, Germany
Source: ClinicalTrials.govStatus changed: Running, not recruiting → Completed
ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study
NCT04431258 · Phase 1/2 · Spain, France, Israel, United States
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599 · Phase 1/2 · Germany, Denmark, Spain, France, United Kingdom, Georgia
Source: ClinicalTrials.govPhase changed: Phase 2/3 → Phase 2
NCT03693677 · Phase 2 · France, Martinique
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
NCT03816163 · Phase 2 · Australia, Brazil, China, Spain, France, Ireland
Source: ClinicalTrials.govPhase changed: Phase 2 → Phase 2/3
Nordic Pancreatic Cancer Trial (NorPACT) - 1
NCT02919787 · Phase 2/3 · Denmark, Finland, Norway, Sweden
Source: ClinicalTrials.govClosed for recruitment
Nordic Pancreatic Cancer Trial (NorPACT) - 1
NCT02919787 · Phase 2/3 · Denmark, Finland, Norway, Sweden
Source: ClinicalTrials.govPhase changed: Phase 1/2 → Phase 2
NCT03175224 · Phase 2 · Australia, Canada, Spain, France, United Kingdom, Hungary
Source: ClinicalTrials.govClosed for recruitment
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171 · Phase 2/3 · Austria, Australia, Belgium, Germany, Spain, France
Source: ClinicalTrials.govOpened for recruitment
NCT05141149 · Phase 1/2 · Australia, Spain, Singapore, United States
Source: ClinicalTrials.govStatus changed: Running, not recruiting → Not yet recruiting
NCT03806309 · Phase 2 · France
Source: ClinicalTrials.govClosed for recruitment
BEFAST Study, [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer
NCT07629609 · Phase 2 · Denmark
Source: ClinicalTrials.govOpened for recruitment
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
NCT04421963 · Phase 3 · Belgium, Bulgaria, Canada, China, Czechia, Germany
Source: ClinicalTrials.govOpened for recruitment
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
NCT04927780 · Phase 3 · Netherlands, Sweden
Source: ClinicalTrials.govOpened for recruitment
Nordic Pancreatic Cancer Trial (NorPACT) - 1
NCT02919787 · Phase 2/3 · Denmark, Finland, Norway, Sweden
Source: ClinicalTrials.govClosed for recruitment
PET-imaging of Two Vartumabs in Patients With Solid Tumors
NCT06645808 · Early Phase 1 · Netherlands
Source: ClinicalTrials.govOpened for recruitment
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185 · Phase 1 · Belgium, Germany, Spain, France, Italy, Japan
Source: ClinicalTrials.govClosed for recruitment
A Study of Evofosfamide in Combination With Zalifrelimab and Balstilimab
NCT06782555 · Phase 1/2 · United States
Source: ClinicalTrials.govStatus changed: Running, not recruiting → Completed
NCT04753879 · Phase 2 · United States
Source: ClinicalTrials.govClosed for recruitment
Prehabilitation in Pancreatic Surgery
NCT06069297 · No phase · Italy
Source: ClinicalTrials.govOpened for recruitment
A Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer
NCT07777211 · Phase 1/2 · China
Source: ClinicalTrials.gov
New reviews, guidelines and randomised trials in PubMed
Meta-analysis
Robotic pancreatic enucleation versus laparoscopic pancreatic enucleation: a meta-analysis.
Journal of robotic surgery · PubMed
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
No phaseEnded 19 Oct 2026
Stopped early64 participants
NCT05058846
Pilot Study of Pancreatic Cancer Screening
Reason given: Slow accrual
Phase 2Ended 9 Oct 2026
Completed40 participants
NCT05659914
Olaparib and durvalumab (MEDI4736) in patients with metastatic pancreatic cancer and DNA Damage Repair genes alterations
Phase 1Ended 9 Oct 2026
Stopped early19 participants
NCT06756035
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Reason given: The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.
Phase 1/2Ended 8 Oct 2026
No phaseEnded 1 Oct 2026
Completed120 participants
NCT07591571
To Evaluate the Preliminary Efficacy of Our Digitally Enhanced CHW-led Intervention in Newly Diagnosed PDAC
Early Phase 1Ended 30 Sept 2026
Withdrawn before start0 participants
NCT04870034
Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer
Reason given: Issues recruiting
Phase 1Ended 22 Sept 2026
Phase 2Ended 21 Sept 2026
Phase 2Ended 20 Sept 2026
Completed32 participants
NCT04820179
Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer
No phaseEnded 1 Sept 2026
No phaseEnded Aug 2026
No phaseEnded 23 Aug 2026
Completed33 participants
NCT06291324
WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment
No phaseEnded 20 Aug 2026
No phaseEnded 16 Aug 2026
Completed100 participants
NCT07139236
Preoperative EUS Elastography for Pancreatic Texture and POPF Prediction After PD
No phaseEnded 11 Aug 2026
Completed103 participants
NCT03902600
A Study of Photon and Proton Chemoradiotherapy as Definitive or Neoadjuvant Therapy in Non-Metastatic Pancreatic Cancer
Phase 1Ended 7 Aug 2026
Withdrawn before start0 participants
NCT05737615
PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9
Reason given: Study tracer is currently unavailable
No phaseEnded 2 Aug 2026
Withdrawn before start0 participants
NCT06054308
Mesothelin-targeted CAR-T Cells as a Neo-adjuvant Treatment in Patients With Resectable Pancreatic Cancers: a Feasibility Study
Reason given: Unable to obtain Clinical Trial Certificate due to tech Unable to obtain Clinical Trial Certificate due to technical difficulties
Phase 1Ended Jul 2026
Withdrawn before start0 participants
NCT06017323
Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma
Reason given: STUDY00006987
No phaseEnded 24 Jul 2026
Completed256 participants
NCT05709197
The Effectiveness of Adding Braun Anastomosis to Standard Child Reconstruction After Pancreatoduodenectomy
Phase 1Ended 21 Jul 2026
Completed196 participants
NCT04104672
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
Show more
Phase 1Ended 8 Jul 2026
Completed27 participants
NCT06399757
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Phase 1Ended 2 Jul 2026
Completed37 participants
NCT05846516
KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer
No phaseEnded 1 Jul 2026
Completed138 participants
NCT05249075
Micro-Tech FNB Needle to Obtain Tissue Specimens of Pancreas Malignancy for Personalized Based Chemotherapy
No phaseEnded 1 Jul 2026
Phase 2Ended 1 Jul 2026
Completed36 participants
NCT04753879
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
No phaseEnded 30 Jun 2026
Completed48 participants
NCT07704021
Safety and Efficacy of EUS-guided Gallbladder Drainage Under Endoscopist-directed Conscious Sedation
Phase 2Ended 29 Jun 2026
Phase 2Ended 28 Jun 2026
Phase 1Ended 18 Jun 2026
Stopped early60 participants
NCT06364696
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
Reason given: Company's strategic decision
Early Phase 1Ended 16 Jun 2026
Stopped early1 participant
NCT05438667
TCR-T Cell Therapy on Advanced Solid Tumors
Reason given: In light of the impending acquisition of the project partner, Shanghai Bintie Biotechnology Co., Ltd., the company has resolved to close all IT centers and discontinue the clinical research project.
Phase 2Ended 16 Jun 2026
Completed104 participants
2023-503905-12-00
Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Solid Tumors
Phase 2Ended 11 Jun 2026
Completed23 participants
NCT01972919
MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer
Phase 2Ended 9 Jun 2026
Stopped early6 participants
NCT06158516
A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
Reason given: This investigator-initiated study closed to recruitment early due to slower-than-anticipated patient accrual.
Phase 1Ended 3 Jun 2026
Completed15 participants
NCT05034627
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Phase 1/2Ended 2 Jun 2026
Completed98 participants
NCT05864144
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Early Phase 1Ended 31 May 2026
Withdrawn before start0 participants
NCT05238831
SMMART Adaptive Clinical Treatment (ACT) Trial
Reason given: Withdrawn due to a change in therapeutic interventions.
Phase 1Ended 27 May 2026
Stopped early19 participants
NCT06466187
A Study of SGN-MesoC2 in Advanced Solid Tumors
Reason given: The trial was terminated for strategic reasons. The decision was not based on any safety concerns
Phase 2Ended 26 May 2026
Completed144 participants
NCT01824875
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Phase 2Ended 23 May 2026
Stopped early12 participants
NCT06015659
ZN-c3 + Gemcitabine in Pancreatic Cancer
Reason given: Study stopped early due to reaching the minimum number of DLTs required for halting the study due to toxicity.
No phaseEnded 19 May 2026
Phase 1Ended 12 May 2026
Stopped early30 participants
NCT06704724
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Reason given: The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns.
No phaseEnded 11 May 2026
Completed80 participants
NCT05675059
Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Pancreatic Cancer Patients
No phaseEnded 1 May 2026
Completed62 participants
NCT07924540
Endoscopic Ultrasound Shear Wave Elastography in Solid Pancreatic Lesions
Phase 1Ended 29 Apr 2026
Stopped early13 participants
NCT05057715
huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer
Reason given: Sponsor decision
Phase 1/2Ended 28 Apr 2026
Phase 2Ended 27 Apr 2026
Withdrawn before start0 participants
NCT04481204
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
Reason given: 0 participants
Phase 1Ended 23 Apr 2026
Stopped early47 participants
NCT06585488
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Reason given: The Sponsor has made the decision to terminate this study due to the lack of promising efficacy, internal prioritization, and highly competitive landscape.
Phase 1Ended 16 Apr 2026
Stopped early68 participants
NCT05983133
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
Reason given: The trial was terminated for strategic reasons. The decision was not based on any safety concerns
Phase 1Ended 10 Apr 2026
Completed46 participants
NCT05085548
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
No phaseEnded 3 Apr 2026
Stopped early40 participants
NCT05275075
Identify microRNAs in Cachexia in Pancreatic Carcinoma
Reason given: Translational scientist left university
Early Phase 1Ended 3 Apr 2026
Stopped early25 participants
NCT04930991
High Dose Omeprazole in Patients With Pancreatic Cancer
Reason given: Translational scientist left university
No phaseEnded Mar 2026
Completed3602 participants
NCT07831694
Postoperative Outcomes After Partial Duodenopancreatectomy Versus Total Pancreatectomy
Phase 1Ended 31 Mar 2026
Stopped early8 participants
NCT06974734
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
Reason given: The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns
Early Phase 1Ended 30 Mar 2026
Completed12 participants
NCT05086250
Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer
Phase 1Ended 30 Mar 2026
Stopped early1 participant
NCT06130254
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Reason given: Sponsor discontinued the trial
No phaseEnded 27 Mar 2026
Completed99 participants
NCT06013228
Trajectories of Fatigue and Quality of Life in People With Both Operable Pancreatic Tumor and Diabetes Mellitus
Phase 1Ended 24 Mar 2026
Completed34 participants
NCT04132505
Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
No phaseEnded 23 Mar 2026
Completed72 participants
NCT05461430
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
No phaseEnded 19 Mar 2026
Completed23 participants
NCT05247164
EUS-guided PORtal Vein Sampling for Circulating Tumor Cells in Pancreatic Cancer Patients
Phase 1Ended 17 Mar 2026
Stopped early85 participants
NCT05827614
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
Reason given: Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safety signal.
Not medical advice. fetched 11 Nov 2026